The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
about
Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemiaSodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.p53 Family and Cellular Stress Responses in Cancer.Global effect of inauhzin on human p53-responsive transcriptomeTargeting p53 by small molecules in hematological malignancies.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Targeting p53-MDM2-MDMX loop for cancer therapy.Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells.Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis.Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways.Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer.Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.
P2860
Q33713544-BBD5A642-FB36-4346-A865-D4E11EE3E349Q33869257-48EEF2A4-9BEF-47FC-AB7E-A93A4081066EQ33903412-F24E6364-836C-43F8-AFD4-0412562F00E6Q34100963-5EE6FFD2-0ECD-40A0-BF36-7D91D2484A48Q34377287-5603CBF6-1C34-4E88-AD0F-E70B1F03090AQ34533232-5BFF03CA-0A84-46A4-B8B7-B78428F412EBQ34636996-64827E15-A825-4207-B11B-9BCE897B9FA1Q34647741-4D9D15C1-CDC9-48D6-A628-8B2FF9822EDEQ35149661-A9832185-D4CF-42AC-99CB-9D25ED0DE334Q36366552-B085FA85-A76D-46D4-831B-85B6B80C411DQ37688589-1A1A7C80-6574-4D85-840B-AEC576B47ACDQ38247168-63D306A6-5AEE-4F22-8D97-29632684892BQ39029498-4815CE77-8367-40FA-9998-8C17A7375020Q39126240-A8501C1D-68E9-453B-B47F-6BD70486AFD2Q45018784-0D368C7C-C3F5-4775-82E5-91F8388945C0Q50053840-B4DDC942-3E31-467F-B130-8A2147DFEB33Q52584348-FD98B867-B4A7-4FBE-9B77-89A2D5FBFF9EQ54113343-13DA4368-A4C6-47FE-A6AA-7729305E043C
P2860
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@ast
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@en
type
label
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@ast
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@en
prefLabel
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@ast
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@en
P2093
P2860
P50
P1433
P1476
The sorafenib plus nutlin-3 co ...... ctively of FLT3 and p53 status
@en
P2093
Claudio Celeghini
Elisabetta Melloni
Francesco Lanza
Manuele Ongari
Maria Grazia di Iasio
Rebecca Voltan
P2860
P304
P356
10.3324/HAEMATOL.2012.062083
P577
2012-06-11T00:00:00Z